Product image of Igzelym (Ticagrelor) supplied by GNH India

Igzelym

Active Ingredient:
Ticagrelor
Origin:
EU

Igzelym (Ticagrelor)

Ticagrelor, the active ingredient in Igzelym, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It reduces thrombotic cardiovascular events in patients with acute coronary syndrome and helps prevent atherothrombotic events in those with a history of myocardial infarction.

GNH India supplies Igzelym as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ticagrelor acts on platelet aggregation pathways to lower the risk of cardiovascular events. It is indicated for the following conditions:

  • Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke.
  • History of myocardial infarction: lowers the incidence of recurrent atherothrombotic events.
  • Patients undergoing percutaneous coronary intervention: helps prevent stent thrombosis and related complications.

How It Works

  • Ticagrelor is a reversible antagonist of the platelet P2Y12 ADP receptor. By binding to this receptor, it blocks ADP‑mediated activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation and thrombus formation without requiring metabolic activation.

Side Effects

Ticagrelor may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Dyspnea: shortness of breath occurring in many patients.
  • Bleeding: including bruising, epistaxis or gastrointestinal bleeding.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Dizziness: transient light‑headedness.
  • Hypotension: occasional drop in blood pressure.

Serious or Rare Side Effects

  • Severe bleeding: life‑threatening hemorrhage such as intracranial bleeding.
  • Allergic reactions: rash, pruritus, or anaphylaxis.
  • Thrombocytopenia: marked reduction in platelet count.
  • Myocardial infarction recurrence: rare cases of worsening ischemia.
  • Hepatic injury: elevated liver enzymes in susceptible individuals.

Precautions & Warnings

Before prescribing Ticagrelor, clinicians should consider several safety measures.

  • Assess bleeding risk: review patient history for active or recent bleeding.
  • Monitor renal function: adjust therapy in severe renal impairment.
  • Avoid in active pathological bleeding: discontinue if uncontrolled hemorrhage occurs.
  • Caution with concomitant anticoagulants: increased risk of major bleeding.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Ticagrelor can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor exposure and bleeding risk.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
  • Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding potential.

Moderate Interactions (Monitor Closely)

  • NSAIDs: additive gastrointestinal bleeding risk.
  • SSRIs or SNRIs: may increase bleeding tendency.
  • Statins metabolised by CYP3A4 (e.g., simvastatin): monitor for possible increased plasma levels.

Frequently Asked Questions

Igzelym contains ticagrelor, an antiplatelet medication used to reduce thrombotic cardiovascular events in patients with acute coronary syndrome and to prevent atherothrombotic complications in individuals who have previously experienced a myocardial infarction.

Ticagrelor reversibly blocks the platelet P2Y12 ADP receptor, preventing ADP‑mediated activation of the GPIIb/IIIa complex. This inhibition reduces platelet aggregation and the formation of clots that can lead to heart attacks or strokes.

The dosage of Igzelym is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the exact regimen provided by their healthcare professional.

The safety of ticagrelor in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Igzelym, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with clopidogrel, ticagrelor provides more rapid and consistent platelet inhibition because it does not require metabolic activation. This can translate into greater efficacy in preventing cardiovascular events, though it may also be associated with a higher incidence of certain side effects such as dyspnea.

Igzelym should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability throughout its shelf life.

Igzelym is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe or life‑threatening bleeding, such as intracranial hemorrhage, and rare allergic reactions that can lead to anaphylaxis. Patients should be monitored closely for signs of uncontrolled bleeding or hypersensitivity.

Igzelym is contraindicated in patients with active pathological bleeding, a history of intracranial hemorrhage, or severe hepatic impairment. It should also be avoided in individuals who are hypersensitive to ticagrelor or any of the tablet’s excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ticagrelor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT